Frazier Life Sciences Management, L.P. Macrogenics Inc Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Macrogenics Inc stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 3,175,665 shares of MGNX stock, worth $7.81 Million. This represents 0.62% of its overall portfolio holdings.
Number of Shares
3,175,665
Previous 3,010,727
5.48%
Holding current value
$7.81 Million
Previous $9.91 Million
4.19%
% of portfolio
0.62%
Previous 0.53%
Shares
7 transactions
Others Institutions Holding MGNX
# of Institutions
131Shares Held
56MCall Options Held
28.3KPut Options Held
197K-
Bellevue Group Ag Kuesnacht, V89.93MShares$24.4 Million0.64% of portfolio
-
Armistice Capital, LLC New York, NY6.28MShares$15.4 Million0.29% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$13.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.32MShares$10.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.49MShares$8.58 Million0.06% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $151M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...